GLOBAL AUTOINJECTORS MARKET TRENDS | INDUSTRY GROWTH, SHARE, SIZE, DEMAND AND OUTLOOK 2022

The global autoinjectors market From USD 46.0 billion in 2022 to USD 104.9 billion in 2028, the market is expected to grow at a CAGR of 17.9%. The rising prevalence of targeted therapies, the rising incidence of anaphylaxis, the rising preference for self-administration of drugs, usability benefits, the growing number of regulatory approvals, the availability of generic versions of autoinjectors, favourable reimbursements and government support, and technological advancements are all driving market growth. Biologics’ patent expiration is also predicted to generate growth prospects for industry competitors.

Access Full Report here : https://www.zionmarketresearch.com/report/autoinjectors-market

The Impact of COVID-19 on the Autoinjectors Market

The COVID-19 pandemic has triggered a global healthcare crisis, with most countries experiencing a shift in healthcare delivery. In order to minimise the spread of the virus and reduce the strain on healthcare infrastructure, most non-essential surgeries and in-hospital therapy were postponed in the first half of 2020. According to Indiana University researchers, healthcare visits in the United States dropped by 40% in the first six weeks of the pandemic, from early March to mid-April. There has been a general decrease in patients postponing seeking care and treatment in healthcare settings after the limits were eased. Furthermore, the slowing enrollment of clinical trial participants has slowed the launch of novel medicines. These factors could have harmed the autoinjector market, particularly with their application in healthcare institutions beginning in early 2020.

However, due to various circumstances, the pandemic’s overall influence on autoinjectors is considered good, especially in the predicted term. To begin with, the demand for effective home care and remote monitoring has increased the importance of autoinjectors as a convenient and easy way for patients to manage chronic illnesses and allergies without having to go to the hospital. Patients with diabetes, Crohn’s disease, and rheumatoid arthritis who use prefilled syringes and autoinjectors to treat their conditions at home have found this to be especially true.

In conclusion, the COVID-19 epidemic has accelerated the trend of self-injection, allowing patients to take a more active role in their treatment. This tendency has been aided by newer technology in the autoinjector market, which allow for improved regulation of injection speed, injection site pain, and treatment anxiety.

Driver: Anaphylaxis is becoming more common.

Anaphylaxis is a severe allergic reaction to food, medicines, latex, and Hymenoptera stings that can be fatal. Anaphylaxis-like responses affect one out of every 1,000 people, according to a NICE research. Anaphylaxis occurs in one out of every 10,000–20,000 general anaesthetics. Unless a safe combination of medicines can be established, these individuals may be denied general anaesthesia in the future. Anaphylaxis has an annual incidence rate of 1.5–50 per 100,000 person-years, according to epidemiological studies. The majority of reports, however, come from Western countries such as the United States, the United Kingdom, and Australia. According to a study published in the European Journal of Allergy and Clinical Immunology in 2019, the incidence of anaphylaxis in children worldwide varied widely, with total anaphylaxis ranging from 1 to 761 per 100,000 person-years and food-related anaphylaxis ranging from 1 to 77 per 100,000 person-years.

Restraint: Modes of alternative medication delivery

Because traditional injectables with vials and syringes are invasive and uncomfortable, patients and healthcare providers are increasingly focused on alternate routes such as oral, topical, and nasal. Oral administration is the preferred method since it is simple to administer, convenient, cost-effective, safe, and acceptable. Furthermore, the emergence of needle-free medication administration technologies such jet injectors has slowed market growth. Antares Pharma, for example, sells growth hormone jet injectors in the United States, Europe, Asia, and Japan.

Opportunity: Patient visits and physical touch must be limited.

The present COVID-19 epidemic has led in the development of a new set of protocols aimed at reducing non-emergency patient visits to hospitals and clinics in order to avoid virus transmission while also ensuring that healthcare institutions are not overburdened. Patients with chronic illnesses and allergies are increasingly turning to home-use autoinjectors in this situation. This also prevents the virus from infecting vulnerable high-risk populations during hospital stays.

Challenge: Autoinjectors for a variety of medication viscosities are being developed.

OEMs confront the most difficult task in producing single-design autoinjectors for a variety of medicines and biologics with various viscosities. To develop a spring rate that offers enough power to push higher-viscosity pharmaceuticals and biologics through the syringe to the needle, springs with diverse physical characteristics such as composition, length, and thickness are required. Most pharmaceutical companies now lack the expertise needed to develop autoinjectors that can deliver various medicines and biologics of varying viscosities. Players, on the other hand, are attempting to overcome this obstacle. For example, the Ypsomate 2-step autoinjector from Ypsomed can be customised for varied fill volumes and viscosities.

Key Market Players

Some of the key players operating in the autoinjectors market include AbbVie Inc. (US), Mylan (US), Eli Lilly and Company (US), Ypsomed (Switzerland), Amgen (US), Becton, Dickinson and Company (US), GlaxoSmithKline plc (UK), Johnson & Johnson (US), Teva Pharmaceutical (Israel), Antares Pharma (US), Merck KGaA (Germany).

The autoinjectors market is divided into the following segments and sub-segments, according to the research report:

By Type

● Reusable Autoinjectors
● Disposable Autoinjectors

By Application

● Hospitals & Clinics
● Home Care Settings
● Ambulatory Care Settings

Read more at : https://www.zionmarketresearch.com/news/autoinjectors-market

Recent Developments

➜ Antares Pharma (US) and Lunatus Global Medical Supplies signed a contract in August 2020. (Dubai). Antares will supply Lunatus with packaged products, and Lunatus will submit and gain regulatory approval for XYOSTED in the UAE and Saudi Arabia, as well as promote, market, and distribute the drug in these two countries.
➜ SHL Medical (Switzerland) bought Weibel CDS in March 2020. (Switzerland). SHL Medical’s ability to provide more advanced medication delivery systems based on human-centered designs and functionality was bolstered by this acquisition.
➜ Eli Lilly invested USD 470 million in Durham, NC in January 2020, creating over 460 new employment. North Carolina’s research triangle park now has a new state-of-the-art pharmaceutical production facility thanks to its development.
➜ Becton, Dickinson and Company (US) launched a disposable autoinjector, the BD Intevia 1ml Disposable Autoinjector, in November 2019. The company’s autoinjector portfolio will be strengthened as a result of this effort.

About Us :

Zion Market Research is an obligated company. We create futuristic, cutting edge, informative reports ranging from industry reports, company reports to country reports. We provide our clients not only with market statistics unveiled by avowed private publishers and public organizations but also with vogue and newest industry reports along with pre-eminent and niche company profiles. Our database of market research reports comprises a wide variety of reports from cardinal industries. Our database is been updated constantly in order to fulfill our clients with prompt and direct online access to our database.

Leave a Comment

Your email address will not be published. Required fields are marked *